ALXO vs. KRRO, RVNC, CTNM, GLUE, ENGN, RGNX, ALMS, TSHA, CRVS, and PGEN
Should you be buying ALX Oncology stock or one of its competitors? The main competitors of ALX Oncology include Korro Bio (KRRO), Revance Therapeutics (RVNC), Contineum Therapeutics (CTNM), Monte Rosa Therapeutics (GLUE), enGene (ENGN), REGENXBIO (RGNX), Alumis (ALMS), Taysha Gene Therapies (TSHA), Corvus Pharmaceuticals (CRVS), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
ALX Oncology vs.
ALX Oncology (NASDAQ:ALXO) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.
ALX Oncology received 25 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 62.82% of users gave ALX Oncology an outperform vote.
Korro Bio's return on equity of -50.25% beat ALX Oncology's return on equity.
98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 33.4% of ALX Oncology shares are owned by insiders. Comparatively, 5.4% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
ALX Oncology has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.
In the previous week, ALX Oncology and ALX Oncology both had 4 articles in the media. ALX Oncology's average media sentiment score of 1.03 beat Korro Bio's score of 0.35 indicating that ALX Oncology is being referred to more favorably in the media.
ALX Oncology currently has a consensus price target of $8.50, indicating a potential upside of 388.51%. Korro Bio has a consensus price target of $144.00, indicating a potential upside of 289.19%. Given ALX Oncology's higher probable upside, analysts clearly believe ALX Oncology is more favorable than Korro Bio.
Summary
Korro Bio beats ALX Oncology on 8 of the 13 factors compared between the two stocks.
Get ALX Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALXO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ALX Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:ALXO) was last updated on 1/20/2025 by MarketBeat.com Staff
